Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. - Wikidata - awgldk - TriplyDB

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

http://www.wikidata.org/entity/Q33384766

about

Systematic review of dasatinib in chronic myeloid leukemia Chronic myeloid leukemia: reminiscences and dreams European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro.Practical management of patients with chronic myeloid leukemia.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.An update on dual Src/Abl inhibitors.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia Chronic myelogenous leukemia: treatment and monitoring.Monitoring response and resistance to treatment in chronic myeloid leukemia.The role of dasatinib in the management of chronic myeloid leukemia Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure How I treat childhood CML.Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma.National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.A Case of Dasatinib-Induced Hemorrhagic Colitis Diagnosed by the Lymphocyte Transformation Test in a Chronic Myeloid Leukemia Patient.Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients Dasatinib-induced pleural effusion: Chylothorax, an option to consider.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.Treatment of chronic myeloid leukemia when imatinib fails.Selection of therapy: rational decisions based on molecular events.Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.Evolution of therapies for chronic myelogenous leukemia.Development of an effective therapy for chronic myelogenous leukemia Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

P2860

Q24596026-C02E1F0B-A36F-40C3-BFE3-E2216385C03E Q26748769-D8BA7FA5-6F42-4B67-A46C-3CDFA83725BE Q26749324-E8CFBDBB-2BB6-4C68-AFF0-DC5E75D331E0 Q27028181-98E39D09-2188-40CE-8C59-CCBB33672CE1 Q33391185-56A14BD5-CFAA-4E6D-9684-FC2B6F339C73 Q33394424-549DAD15-26D6-45EC-A15A-F245B06F25C5 Q33397085-34A2B29F-41F8-409A-9583-DA3D79D88B06 Q33399101-DB70086E-BFE7-4607-AD7F-E97B04A57BAB Q33655352-09FCFAFD-FC34-4A1E-BC67-370926AFE8F9 Q33744855-872317A2-B473-4470-87D0-39C618E881A3 Q33849146-8D9316DE-0A5A-47FE-9FCE-F79F76770244 Q33926114-FDD8964D-806E-45B5-8EAC-7215EB035419 Q34270677-947172E3-CD8D-488C-ACF1-D1DABAA84E61 Q34293414-82E3C480-2553-42BE-9A8C-BBFADE88FC83 Q34522789-5F3C438E-CC55-4450-A98A-5AC85454923F Q34617628-FDA9EAC2-E264-4F45-9F3D-B0B85BA3492E Q34761663-1E3683D3-C21D-48EF-A2F1-E19C44D0A4BD Q35087994-2B35516E-EB02-4F91-8E64-F6A18DCB981B Q35510549-85C06AEF-34C6-4A54-87AD-7BD715A27938 Q35596200-5478A993-C9D2-49D7-B182-3A42B0146038 Q35802202-AB97301D-40CE-4E51-B9FE-9A8A9539EAD1 Q36014173-A762ED76-7615-492A-9C32-C2C9E5A9D8EC Q36125906-185D718F-7E0C-46CD-BD3F-3870B42B2B9D Q36462473-DEB7FA7E-2E5F-4F3E-836A-CF20DF7467E8 Q36800451-FBAC7679-5F65-4900-9AE2-37EB0EE9DC39 Q37026032-33707665-C988-4690-915D-A0A0CFD6E47B Q37048378-553104C5-263E-4ECB-924D-EABBB57A5691 Q37139374-70164F3F-B61C-4B98-A615-A598666B6357 Q37350583-97657C51-6C82-418F-8643-CCE2031C858C Q37461942-669F3A45-3526-4990-B139-6A701423C797 Q37647076-29781319-A14F-4A7D-9D91-5E75E5C39215 Q37781050-3EDFCD73-E57C-4DDF-ACE1-340FC6263E25 Q37797981-FFE19688-E299-4F38-999C-5D1F13638E45 Q37810070-C531E9BC-5C60-48B6-A696-C1A632DF04EA Q37827875-3C5A3662-27C7-4166-AF59-EB0B4118708D Q37952910-317EA8E7-40D7-407B-A668-7FFE912311F1 Q37965564-49F49EEE-7119-4ECD-9CE1-EBBDD79BFE52 Q37966915-49A0809A-AE48-48D2-9D21-22710614FFE7 Q37966917-0BBA5499-C40C-4E00-8514-DF577D3E7A66 Q37988569-98CA3FFF-0B63-4E07-8A30-68C18862D28E

P2860

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

http://www.wikidata.org/entity/Q33384766

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Dasatinib in the treatment of ...... ib failure: the START a trial.

@ast

Dasatinib in the treatment of ...... ib failure: the START a trial.

@en

type

label

Dasatinib in the treatment of ...... ib failure: the START a trial.

@ast

Dasatinib in the treatment of ...... ib failure: the START a trial.

@en

prefLabel

Dasatinib in the treatment of ...... ib failure: the START a trial.

@ast

Dasatinib in the treatment of ...... ib failure: the START a trial.

@en

P1433

Q33384766-13A4130A-C975-41C2-9C56-CA2DB795C8C1

P1476

Q33384766-5EE123E0-689E-4F35-A366-2A4E53FF802D

P2093

Q33384766-13730D9E-18C9-4ABF-984C-F314DEA56AE9

Q33384766-16D763DB-7689-4EB1-998F-6978722A1931

Q33384766-234DFBA1-6030-482E-A814-CB3B6B0D056A

Q33384766-2EEEEBE3-E91E-451B-98B7-7B239DB6F3F3

Q33384766-47101D5A-9860-4247-9A3D-839D063D07BD

Q33384766-4A642870-63F4-46D1-8737-2FA6BE739928

Q33384766-5D5942DA-10CB-4AD7-B6DE-C030B3DD5B8C

Q33384766-7901BFD4-C905-478E-831F-4DBB9EC0E5B7

Q33384766-986CAC77-11BA-414A-869F-AD4DA911ED39

Q33384766-9AB0AC80-E501-419A-BE2F-7E3159106F46

P2860

Q33384766-29C19EBA-F3D1-4030-A073-95CCA3DEDC87

Q33384766-2A6B273E-88E3-430F-99A2-024D5C3ABAFE

Q33384766-2FBA017A-8795-4B35-AFBD-6B0D8E896EB0

Q33384766-3993FBC2-5B33-4114-B6F1-2256C1DDFDEC

Q33384766-495D2CAD-7680-46B7-9BB9-C0C0C66A999F

Q33384766-5A02EF92-E4EF-4919-A99B-94C0B5E5895C

Q33384766-5E90CCC8-4FCC-4073-A862-C4000486C3BB

Q33384766-633D0399-751D-47CD-A893-06AD8583F52F

Q33384766-648E4DB9-8FA8-403C-8568-26351935D72D

Q33384766-6842FA8D-269C-498C-8B49-57DA6A01550F

P304

Q33384766-7D04FB5C-7807-41D9-BF52-B13DB5C02784

P31

Q33384766-CE624EBC-CB48-40A3-BD40-62CCD329B35A

P356

Q33384766-A3064713-50B4-4FE1-BE91-22BBACE6D077

P407

Q33384766-7D527365-F711-41A0-8507-B58C1D539CCE

P433

Q33384766-D2841080-4508-4531-85D1-72C188EEB28A

P478

Q33384766-543D41A7-8C39-4EDF-B4F8-DC4A0013B4EB

P50

Q33384766-02403EFE-BA69-49E0-B7AC-39632E85AC2B

Q33384766-19118594-F0C3-4D25-9436-F8B7E225EB51

Q33384766-4900731F-FD12-4125-A687-D61CC274F8DC

Q33384766-6AC29F0B-E658-4489-8AB6-EFA858284A03

Q33384766-DEFC1708-F48E-44AE-BB6F-E0474523A5FB

P577

Q33384766-4ED974F4-B366-4150-BAA3-EA8A5CEAF985

P698

Q33384766-17F72D39-2E20-41E3-A106-DB33632D9AC8

P921

Q33384766-2268B551-523B-4C5C-B55C-3282FEEF61A0

Q33384766-8CE42783-9991-433C-9275-39C36EC37ECE

P932

Q33384766-71BBBD00-4297-449A-863E-5CC257ACD444

P356

JCO.2007.14.3339

P1433

Journal of Clinical Oncology

P1476

Dasatinib in the treatment of ...... ib failure: the START a trial.

@en

P2093

Carmino A de Souza

http://www.w3.org/2001/XMLSchema#string

Christian Sillaber

http://www.w3.org/2001/XMLSchema#string

Dominik Heim

http://www.w3.org/2001/XMLSchema#string

Dong-Wook Kim

http://www.w3.org/2001/XMLSchema#string

Eduardo O Bullorsky

http://www.w3.org/2001/XMLSchema#string

Gail J Roboz

http://www.w3.org/2001/XMLSchema#string

H Jean Khoury

http://www.w3.org/2001/XMLSchema#string

Hyeoung-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Jan Van Tornout

http://www.w3.org/2001/XMLSchema#string

Jane F Apperley

http://www.w3.org/2001/XMLSchema#string

P2860

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Overriding imatinib resistance with a novel ABL kinase inhibitor

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Tra

Gene expression changes associated with progression and response in chronic myeloid leukemia.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.

P304

3472-3479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.3339

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Richard A. Larson

Elisabetta Abruzzese

Jorge Eduardo Cortes

Gianantonio Rosti

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19487385

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

4979080

http://www.w3.org/2001/XMLSchema#string